Research News on Hormonal Therapy
-
Drop in Breast Density Key to Tamoxifen Lowering Risk
A new study suggests that tamoxifen is successful at reducing breast cancer risk only in high-risk women whose breast density decreases by 10% or more during the first year or so of treatment.
-
Aromasin Slightly Better than Tamoxifen at Reducing Recurrence Risk
Research shows that the aromatase inhibitor Aromasin reduces the risk of the cancer coming back somewhat better than tamoxifen in post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Femara and Tykerb Combo Better Than Femara Alone for Metastatic Hormone-Receptor-Positive, HER2-Positive Cancers
A new study shows that treating hormone-receptor-positive, HER2-positive metastatic breast cancer with the combination of Femara and Tykerb offers more benefits than Femara alone.
-
Aromatase Inhibitors Slightly Better Than Tamoxifen for Postmenopausal Women
A review of a number of studies confirms that aromatase inhibitors reduce the risk of early-stage, hormone-receptor-positive breast cancer coming back better than tamoxifen in post-menopausal women.
-
Estradiol May Make Breast Cancer Start Responding to Aromatase Inhibitors Again
A small study found that estradiol, a form of estrogen, can make advanced-stage, hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again in some cases.
-
Experimental Bone Medicine May Lower Risk
A new selective estrogen receptor modulator (SERM) called Oporia (chemical name: lasofoxifene) has been shown to improve bone health and reduce the risk of breast cancer, especially hormone-receptor-positive breast cancer, in post-menopausal women.
-
Lab Study Looks at Why Cancers Become Resistant to Tamoxifen
Basic laboratory research has found that certain invasive lobular breast cancers may not respond to tamoxifen because they develop a protein receptor that stops tamoxifen from working.
-
Hormonal Therapy Side Effects Linked to Lower Risk of Recurrence
New research suggests a link between hormonal therapy side effects (hot flashes, night sweats, joint pain) and a reduced risk of breast cancer coming back.
-
Zoladex May Help Reduce Risk of Recurrence
After surgery and other treatments for hormone-receptor-positive early-stage breast cancer in premenopausal women, treatment with the hormonal therapy medicine Zoladex (chemical name: goserelin) can lower the risk of the cancer coming back and improve overall prognosis.
-
Protective Tamoxifen May Lead to Earlier Diagnosis of Hormone-Receptor-Negative Cancer
Women at high risk who took tamoxifen and developed hormone-receptor-NEGATIVE breast cancer had the cancer diagnosed earlier compared to women who didn't take tamoxifen. (Tamoxifen doesn't reduce the risk of hormone-receptor-negative breast cancer.)
